Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
Elisabet de los Pinos, President and CEO of Aura Biosciences , Inc. (NASDAQ:AURA), a $397 million market cap biotechnology company with strong liquidity indicators according to InvestingPro, has sold 20,221 shares of the company’s common stock. The shares were sold at a weighted average price of $7.7541, generating a total value of $156,795. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units and was not at the discretion of de los Pinos. The company maintains a healthy balance sheet with more cash than debt and a robust current ratio of 12.47x. Following the sale, de los Pinos holds 482,440 shares directly and an additional 127,763 shares indirectly through the Elisabet de los Pinos Revocable Trust. Wall Street analysts maintain a bullish outlook on AURA, with price targets ranging from $20 to $23 - discover more detailed analysis and financial insights with InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.